WAXMAN, SCHUMER PUSH BIOPHARMACEUTICAL LEGISLATION

Published Online: Wednesday, November 1, 2006

Congressional generic drug advocates are pushing for legislation for creating new fast-track procedures for the FDA to use in approving generic biopharmaceuticals for marketing. The bill, introduced by Rep Henry Waxman (D, Calif) and Sen Charles Schumer (D, NY) as the "Access to Life-Saving Medicine Act," could save billions of dollars for consumers and taxpayers by establishing a clear, efficient abbreviated pathway for approval of generic versions of such biopharmaceuticals as Epogen (epoetin alfa), Neupogen (filgrastim), and Avonex (interferon β-1a).

Although biopharmaceuticals hold the promise of improving the lives of millions of patients, they can be prohibitively expensive. Noting that some of these treatments cost up to $100,000 per year, a spokesman for the Generic Pharmaceutical Association (GPhA) said that "without generic versions, the costs will cripple the health care system and keep needed treatments out of the hands of consumers."

Likening the proposed new legislation to the landmark 1984 Hatch-Waxman Act, GPhA President Kathleen Jaeger said that now "Congress has the opportunity again to help countless Americans access lifesaving biopharmaceuticals that are safe, effective, and affordable."




Latest Articles
This weekly video program highlights the latest in pharmacy news, product news, and more.
Propranolol is red, digoxin is blue. Your pharmacist’s heart may skip a beat if they get a valentine from you.
Health-system pharmacists can play a critical role in managing drug shortages to prevent medical errors and adverse events.
The White House is asking Congress for more than $1.8 billion in emergency funding to combat the Zika virus, which is creeping into the United States and ravaging some foreign countries.
Latest Issues
$auto_registration$
VSEO N/A